Ozempic health benefits beyond weight loss: What the evidence shows

Ozempic (semaglutide) is best known for diabetes control and weight loss, but a growing body of clinical evidence shows benefits that go further — including reductions in heart attack, stroke, and major kidney events.^1,2 The FDA has now approved semaglutide for several non-weight indications, and ongoing trials are studying its role in heart failure, sleep apnea, and liver disease.

What is semaglutide and how does it work?

Semaglutide is a GLP-1 receptor agonist that mimics a gut hormone (glucagon-like peptide-1). It improves blood sugar control by stimulating insulin and suppressing glucagon, slows stomach emptying, and acts on appetite centers in the brain.³ It's sold under brand names that include Ozempic and Rybelsus (type 2 diabetes) and Wegovy (chronic weight management and cardiovascular risk reduction).

Does Ozempic reduce heart attack and stroke risk?

Yes — in two large randomized trials, semaglutide reduced major adverse cardiovascular events. In adults with type 2 diabetes, semaglutide reduced major cardiovascular events or death by roughly 26% compared with placebo. In adults with overweight or obesity and established cardiovascular disease but without diabetes, a similar trial found a 20% reduction.¹ The FDA has updated the label for Wegovy to reflect cardiovascular risk reduction in adults with overweight or obesity and established cardiovascular disease.

Does Ozempic protect the kidneys?

In adults with type 2 diabetes and chronic kidney disease, semaglutide is used to lower the risk of worsening kidney disease, kidney failure, and cardiovascular death. Trial results show a slower decline in kidney function and improvements in kidney-specific outcomes.¹ Patients should still avoid dehydration from vomiting or diarrhea, which can worsen kidney function on any GLP-1.

Can Ozempic improve heart failure symptoms?

Semaglutide has been studied in obesity-related heart failure with preserved ejection fraction (HFpEF), both with and without diabetes. Studies suggest improvements in symptoms such as fatigue, shortness of breath, and swelling, along with better physical function and exercise tolerance.²

What about inflammation, blood pressure, and cholesterol?

Beyond glucose and weight, semaglutide is associated with reductions in inflammatory markers, modest decreases in blood pressure, and improvements in lipid profile. Researchers attribute these effects to weight loss as well as direct effects on the cardiovascular system and immune signaling.⁴

Is Ozempic being studied for other conditions?

Active or upcoming research is examining semaglutide for polycystic ovary syndrome (PCOS), substance use disorders, Alzheimer's disease, Parkinson's disease, obstructive sleep apnea, and metabolic dysfunction–associated steatotic liver disease (MASLD).² None of these are currently FDA-approved indications, and any "off-label" use should be discussed with a clinician.

Are these benefits the same as weight loss?

Some benefits are driven by weight loss; others appear to be independent. For example, glucose control begins early, before substantial weight loss has occurred, and cardiovascular benefits in trials have been seen even after adjusting for weight change.⁵ In practice, expect to see overlapping effects on weight, blood pressure, lipids, and inflammation.

Who should not take Ozempic?

Semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. It should be used with caution in patients with a history of pancreatitis, severe gastrointestinal disease, or diabetic retinopathy.⁵ Compounded and counterfeit GLP-1s are not FDA-approved and may not deliver these benefits safely.

Next steps

If you're already taking a GLP-1 for diabetes or weight, talk with your primary care or endocrinology team about whether you're also a candidate for cardiovascular or kidney protective dosing. Need quick same-day care for a side effect? Find an urgent care near you on Solv.